Stock Yards Bank & Trust Co. Has $6.17 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Stock Yards Bank & Trust Co. lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 22.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 120,226 shares of the biopharmaceutical company’s stock after selling 35,760 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Bristol-Myers Squibb were worth $6,169,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. boosted its stake in Bristol-Myers Squibb by 48.0% in the 4th quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock valued at $401,806,000 after buying an additional 2,540,360 shares in the last quarter. AustralianSuper Pty Ltd acquired a new position in Bristol-Myers Squibb in the fourth quarter worth $86,965,000. Mizuho Markets Americas LLC acquired a new position in Bristol-Myers Squibb in the third quarter worth $82,405,000. Northern Trust Corp boosted its stake in Bristol-Myers Squibb by 5.8% in the third quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock worth $1,467,989,000 after purchasing an additional 1,394,158 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Bristol-Myers Squibb by 8.6% in the third quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company’s stock worth $905,806,000 after purchasing an additional 1,240,902 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.9 %

Shares of NYSE:BMY traded up $0.45 during mid-day trading on Monday, reaching $49.38. 3,763,482 shares of the stock were exchanged, compared to its average volume of 15,551,808. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The company has a market cap of $100.08 billion, a P/E ratio of 12.78, a P/E/G ratio of 1.48 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The stock’s 50 day simple moving average is $51.23 and its 200-day simple moving average is $51.43.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb’s quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the company earned $1.82 earnings per share. As a group, equities research analysts predict that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.86%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on BMY. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Wells Fargo & Company upped their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Bank of America lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.